RxDoctor Payments Data

Chantal El Amm, MD

Cardiovascular Disease · Cleveland, OHNPI 1104017383

Payments from drug & device makers

$6,776in general payments, 2019–2025

Across 153 payments — averaging $44.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Abiomed$1K
  • Pfizer$423
  • Johnson & Johnson$182
  • Medtronic$173
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$172
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$1,94529%
  • Food & beverage$4,82471%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,776 in reported general payments places this provider in the 70th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$47,645
Medicare patients
211
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan95$105,029
FarxigaDapagliflozin Propanediol41$44,988
EliquisApixaban20$22,035
JardianceEmpagliflozin16$20,107
Sirolimus16$5,023
Tacrolimus22$3,460
Torsemide34$1,141
Hydralazine Hcl74$1,134
Metoprolol Succinate52$843
Nifedipine ErNifedipine37$586
Carvedilol81$540
Digoxin12$494
Atorvastatin Calcium39$377
Amiodarone Hcl12$325
Spironolactone68$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$62$105,02995 claims
AstraZenecaFarxiga$143$44,98841 claims
PfizerEliquis$423$22,03520 claims
Boehringer IngelheimJardiance$92$20,10716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →